Entera Bio (ENTX) Operating Leases (2019 - 2026)
Entera Bio's (ENTX) quarterly Operating Leases came in at $263000.0 in Q1 2026, up 415.69% YoY from $51000.0 in Q1 2025, and up 1.15% on a QoQ basis from $260000.0 in Q4 2025.
Entera Bio (ENTX) Operating Leases (2019 - 2026) Analysis & Trends
Entera Bio (ENTX) has 8 years of Operating Leases data on file, last reported at $263000.0 in Q1 2026.
- Quarterly Operating Leases rose 415.69% year-over-year to $263000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $263000.0 (up 415.69% YoY) and the FY2025 annual result came in at $260000.0, down 4.41% from the prior year.
- Operating Leases grew to $263000.0 in Q1 2026, from $260000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $456000.0 in Q2 2023 to a low of $3000.0 in Q3 2022.
- A 5-year average of $180687.5 and a median of $163000.0 in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases slumped 98.65% — and 2023, when it surged 13300.0%.
- Tracing ENTX's Operating Leases over 5 years: stood at $91000.0 in 2022, then soared by 328.57% to $390000.0 in 2023, then tumbled by 30.26% to $272000.0 in 2024, then dropped by 4.41% to $260000.0 in 2025, then climbed by 1.15% to $263000.0 in 2026.
- The last three Operating Leases figures came in at $263000.0 (Q1 2026), $260000.0 (Q4 2025), and $41000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - |
| 10 | Entera Bio | 164.47 Mn | 153.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 226,000.00 |
| Mar 31, 2026 | 263,000.00 |
| Dec 31, 2025 | 260,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Dec 31, 2024 | 272,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Jun 30, 2024 | 179,000.00 |
| Mar 31, 2024 | 224,000.00 |
| Dec 31, 2023 | 390,000.00 |
| Sep 30, 2023 | 402,000.00 |
| Jun 30, 2023 | 456,000.00 |
| Dec 31, 2022 | 91,000.00 |
| Sep 30, 2022 | 3,000.00 |
| Jun 30, 2022 | 5,000.00 |
| Mar 31, 2022 | 98,000.00 |
| Dec 31, 2021 | 302,000.00 |
| Jun 30, 2021 | 371,000.00 |
| Dec 31, 2020 | 432,000.00 |